HOME › DRUGS › ALEMTUZUMAB
ACTIVE SUBSTANCE / INN

ALEMTUZUMAB

Brand name(s): Lemtrada, LEMTRADA, CAMPATH, MabCampath
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
AUTHORISED
Multiple Sclerosis
Leukemia, Lymphocytic, Chronic, B-Cell
ACTIVE SUBSTANCE
Alemtuzumab
REGULATORS
FDA · EMA
SPONSORS / MAH
Genzyme Europe B.V., GENZYME, Sanofi Belgium
TOTAL APPLICATIONS
4
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
LEMTRADABLA103948GENZYMEPrescription
CAMPATHBLA103948GENZYMEPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
LemtradaSanofi BelgiumAuthorised12/09/2013Multiple Sclerosis
MabCampathGenzyme Europe B.V.Withdrawn06/07/2001Leukemia, Lymphocytic, Chronic, B-Cell

FULL INTELLIGENCE ON ALEMTUZUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →